Differences Between Polycythemia Vera and Essential Thrombocythemia

Publication
Video
Special ReportsHematologic Malignancies: Polycythemia Vera
Volume 3
Issue 3

Heinz Gisslinger, MD, Medical University of Vienna, discusses differences between polycythemia vera (PV) and essential thrombocythemia (ET).

Articles in this issue
Differences Between Polycythemia Vera and Essential Thrombocythemia
Differences Between Polycythemia Vera and Essential Thrombocythemia
Experts Debate Need for New Drugs to Treat Patients with PV and ET
Experts Debate Need for New Drugs to Treat Patients with PV and ET
Gaining More Benefit from Ruxolitinib for Patients With Polycythemia Vera, Other MPNs
Gaining More Benefit from Ruxolitinib for Patients With Polycythemia Vera, Other MPNs
Management of ET, PV Requires 2 Distinct Approaches
Management of ET, PV Requires 2 Distinct Approaches
Expert Discusses Recent Developments in Polycythemia Vera
Expert Discusses Recent Developments in Polycythemia Vera
Ruxolitinib Beats Out Best Available Therapy in Polycythemia Vera
Ruxolitinib Beats Out Best Available Therapy in Polycythemia Vera
Significant Developments in Treating PV
Significant Developments in Treating PV

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Frontline Dato-DXd Looks Promising in NSCLC

Frontline Dato-DXd Looks Promising in NSCLC

Morgan Bayer
May 13th 2025
Article

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Read More

T-DXd’s Robust Efficacy and Response Continue in Frontline MBC

T-DXd’s Robust Efficacy and Response Continue in Frontline MBC

Tony Berberabe, MPH
May 13th 2025
Article

T-DXd monotherapy and T-DXd plus pertuzumab continue to show robust efficacy in HER2-positive metastatic breast cancer.

Read More

Novel Combinations Highlight Treatment Advances in Melanoma

Novel Combinations Highlight Treatment Advances in Melanoma

Tony Berberabe, MPH
May 12th 2025
Article

Read More

Overall Experience: Elevating the Patient Encounter

Overall Experience: Elevating the Patient Encounter

Kemia Zeinali, DMD, MBA
May 12th 2025
Article

Branding in the health care industry should prioritize communicating empathy and care through every touchpoint.

Read More

The Oncology Community Faces Unusual Uncertainty

The Oncology Community Faces Unusual Uncertainty

Robert L. Ferris, MD, PhD
May 10th 2025
Article

The field of cancer research and treatment is, almost by definition, continually evolving.

Read More

FDA Fast-Tracks Givinostat for Polycythemia Vera Treatment

FDA Fast-Tracks Givinostat for Polycythemia Vera Treatment

Jordyn Sava
May 8th 2025
Article

The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in the ongoing phase 3 GIV-IN PV trial.

Read More